GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » ROE %

Manhattan Scientifics (Manhattan Scientifics) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Manhattan Scientifics's annualized net income for the quarter that ended in Dec. 2023 was $-1.02 Mil. Manhattan Scientifics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-2.73 Mil. Therefore, Manhattan Scientifics's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Manhattan Scientifics's ROE % or its related term are showing as below:

During the past 13 years, Manhattan Scientifics's highest ROE % was 235.16%. The lowest was -208.06%. And the median was -39.77%.

MHTX's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.25
* Ranked among companies with meaningful ROE % only.

Manhattan Scientifics ROE % Historical Data

The historical data trend for Manhattan Scientifics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics ROE % Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 235.16 -127.48 - -

Manhattan Scientifics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Manhattan Scientifics's ROE %

For the Medical Devices subindustry, Manhattan Scientifics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Manhattan Scientifics's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Manhattan Scientifics's ROE % distribution charts can be found below:

* The bar in red indicates where Manhattan Scientifics's ROE % falls into.



Manhattan Scientifics ROE % Calculation

Manhattan Scientifics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1.165/( (-1.695+-2.86)/ 2 )
=-1.165/-2.2775
=N/A %

Manhattan Scientifics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-1.016/( (-2.606+-2.86)/ 2 )
=-1.016/-2.733
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Manhattan Scientifics  (OTCPK:MHTX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.016/-2.733
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.016 / 0)*(0 / 0.374)*(0.374 / -2.733)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.016/-2.733
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.016 / -1.016) * (-1.016 / -0.604) * (-0.604 / 0) * (0 / 0.374) * (0.374 / -2.733)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.6821 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Manhattan Scientifics ROE % Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Manhattan Scientifics (Manhattan Scientifics) Business Description

Traded in Other Exchanges
N/A
Address
244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The company is focused on technology transfer and commercialization of transformative technologies.
Executives
Chris Theoharis director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias director, officer: Chief Executive Officer 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow director, 10 percent owner, officer: Chief Executive Office MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich director, officer: Treasurer MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson director 641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz director 152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg 10 percent owner 1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach director, officer: Secretary MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics (Manhattan Scientifics) Headlines

No Headlines